Human Phenotype Ontology 
Grandparent Node:
expand
Abnormality of renal excretion (HP:0011036)help
Parent Node:
expand
Abnormal urine output (HP:0012590)help
..Starting node
..expand
Decreased urine output (HP:0011037)help
Term ID: 11037
Name: Decreased urine output
Synonym:
Definition: A decreased rate of urine production.
Comments:
Reference: HP:0011037
Genes and Diseases:
 
       Child Nodes:
........expandAnuria (HP:0100519) help
........expandOliguria (HP:0100520) help

 Sister Nodes: 
..expandPolyuria (HP:0000103) help
InputHPO IDHPO termDistanceGeneGene id entrezHGNC IDDiseaseIdDiseaseNameFrequencyOnsetHGMD variantsClinVar variants
 
HPO disease - gene - phenotype typical associations:
 
HPO disease - gene - phenotype less frequent non-typical associations:
HP:0011037HP:0011037Decreased urine output0ACE CL E G H16362707OMIM:267430Renal tubular dysgenesis113
HP:0011037HP:0011037Decreased urine output0AGT CL E G H183333OMIM:267430Renal tubular dysgenesis48
HP:0011037HP:0011037Decreased urine output0AGTR1 CL E G H185336OMIM:267430Renal tubular dysgenesis33
HP:0011037HP:0011037Decreased urine output0APRT CL E G H353626ORPHA:976Adenine phosphoribosyltransferase deficiency19
HP:0011037HP:0011037Decreased urine output0APRT CL E G H353626OMIM:614723Adenine phosphoribosyltransferase deficiency19
HP:0011037HP:0011037Decreased urine output0C3 CL E G H7181318OMIM:612925Hemolytic uremic syndrome, atypical, susceptibility to, 592
HP:0011037HP:0011037Decreased urine output0CAV1 CL E G H8571527ORPHA:220393Diffuse cutaneous systemic sclerosis11
HP:0011037HP:0011037Decreased urine output0CCN2 CL E G H14902500ORPHA:220393Diffuse cutaneous systemic sclerosis
HP:0011037HP:0011037Decreased urine output0CCR6 CL E G H12351607ORPHA:220393Diffuse cutaneous systemic sclerosis
HP:0011037HP:0011037Decreased urine output0CD46 CL E G H41796953OMIM:612922Hemolytic uremic syndrome, atypical, susceptibility to, 239
HP:0011037HP:0011037Decreased urine output0CFB CL E G H6291037OMIM:612924Hemolytic uremic syndrome, atypical, susceptibility to, 430
HP:0011037HP:0011037Decreased urine output0CFH CL E G H30754883OMIM:235400Hemolytic uremic syndrome, atypical, susceptibility to, 186
HP:0011037HP:0011037Decreased urine output0CFHR1 CL E G H30784888OMIM:235400Hemolytic uremic syndrome, atypical, susceptibility to, 1
HP:0011037HP:0011037Decreased urine output0CFHR3 CL E G H1087816980OMIM:235400Hemolytic uremic syndrome, atypical, susceptibility to, 1
HP:0011037HP:0011037Decreased urine output0CFI CL E G H34265394OMIM:612923Hemolytic uremic syndrome, atypical, susceptibility to, 357
HP:0011037HP:0011037Decreased urine output0COX1 CL E G H45127419ORPHA:99845Genetic recurrent myoglobinuria
HP:0011037HP:0011037Decreased urine output0COX3 CL E G H45147422ORPHA:99845Genetic recurrent myoglobinuria
HP:0011037HP:0011037Decreased urine output0DZIP1L CL E G H19922126551ORPHA:731Autosomal recessive polycystic kidney disease4
HP:0011037HP:0011037Decreased urine output0HLA-DRB1 CL E G H31234948ORPHA:220393Diffuse cutaneous systemic sclerosis2
HP:0011037HP:0011037Decreased urine output0IRF5 CL E G H36636120ORPHA:220393Diffuse cutaneous systemic sclerosis4
HP:0011037HP:0011037Decreased urine output0LPIN1 CL E G H2317513345ORPHA:99845Genetic recurrent myoglobinuria95
HP:0011037HP:0011037Decreased urine output0MYH11 CL E G H46297569OMIM:619351MEGACYSTIS-MICROCOLON-INTESTINAL HYPOPERISTALSIS SYNDROME 2; MMIHS2418
HP:0011037HP:0011037Decreased urine output0PAX2 CL E G H50768616ORPHA:97362Renal hypoplasia, bilateral39
HP:0011037HP:0011037Decreased urine output0PBX1 CL E G H50878632ORPHA:97362Renal hypoplasia, bilateral3
HP:0011037HP:0011037Decreased urine output0PKHD1 CL E G H53149016ORPHA:731Autosomal recessive polycystic kidney disease563
HP:0011037HP:0011037Decreased urine output0REN CL E G H59729958OMIM:267430Renal tubular dysgenesis25
HP:0011037HP:0011037Decreased urine output0RYR1 CL E G H626110483ORPHA:466650Exercise-induced malignant hyperthermia1200
HP:0011037HP:0011037Decreased urine output0SLC22A12 CL E G H11608517989OMIM:220150Hypouricemia, renal, 156
HP:0011037HP:0011037Decreased urine output0SLC25A20 CL E G H7881421ORPHA:159Carnitine-acylcarnitine translocase deficiency40
HP:0011037HP:0011037Decreased urine output0THBD CL E G H705611784OMIM:612926Hemolytic uremic syndrome, atypical, susceptibility to, 660
HP:0011037HP:0100519Anuria1ACE CL E G H16362707OMIM:267430Renal tubular dysgenesis.113
HP:0011037HP:0100519Anuria1AGT CL E G H183333OMIM:267430Renal tubular dysgenesis.48
HP:0011037HP:0100519Anuria1AGTR1 CL E G H185336OMIM:267430Renal tubular dysgenesis.33
HP:0011037HP:0100520Oliguria1APRT CL E G H353626OMIM:614723Adenine phosphoribosyltransferase deficiency19
HP:0011037HP:0100520Oliguria1APRT CL E G H353626ORPHA:976Adenine phosphoribosyltransferase deficiencyHP:0040283 - Occasional19
HP:0011037HP:0100519Anuria1C3 CL E G H7181318OMIM:612925Hemolytic uremic syndrome, atypical, susceptibility to, 5.92
HP:0011037HP:0100520Oliguria1CAV1 CL E G H8571527ORPHA:220393Diffuse cutaneous systemic sclerosisHP:0040281 - Very frequent11
HP:0011037HP:0100520Oliguria1CCN2 CL E G H14902500ORPHA:220393Diffuse cutaneous systemic sclerosisHP:0040281 - Very frequent
HP:0011037HP:0100520Oliguria1CCR6 CL E G H12351607ORPHA:220393Diffuse cutaneous systemic sclerosisHP:0040281 - Very frequent
HP:0011037HP:0100519Anuria1CD46 CL E G H41796953OMIM:612922Hemolytic uremic syndrome, atypical, susceptibility to, 2.39
HP:0011037HP:0100519Anuria1CFB CL E G H6291037OMIM:612924Hemolytic uremic syndrome, atypical, susceptibility to, 4.30
HP:0011037HP:0100519Anuria1CFH CL E G H30754883OMIM:235400Hemolytic uremic syndrome, atypical, susceptibility to, 1.86
HP:0011037HP:0100519Anuria1CFHR1 CL E G H30784888OMIM:235400Hemolytic uremic syndrome, atypical, susceptibility to, 1.
HP:0011037HP:0100519Anuria1CFHR3 CL E G H1087816980OMIM:235400Hemolytic uremic syndrome, atypical, susceptibility to, 1.
HP:0011037HP:0100519Anuria1CFI CL E G H34265394OMIM:612923Hemolytic uremic syndrome, atypical, susceptibility to, 3.57
HP:0011037HP:0100520Oliguria1COX1 CL E G H45127419ORPHA:99845Genetic recurrent myoglobinuria
HP:0011037HP:0100520Oliguria1COX3 CL E G H45147422ORPHA:99845Genetic recurrent myoglobinuria
HP:0011037HP:0100520Oliguria1DZIP1L CL E G H19922126551ORPHA:731Autosomal recessive polycystic kidney diseaseHP:0040283 - Occasional4
HP:0011037HP:0100520Oliguria1HLA-DRB1 CL E G H31234948ORPHA:220393Diffuse cutaneous systemic sclerosisHP:0040281 - Very frequent2
HP:0011037HP:0100520Oliguria1IRF5 CL E G H36636120ORPHA:220393Diffuse cutaneous systemic sclerosisHP:0040281 - Very frequent4
HP:0011037HP:0100520Oliguria1LPIN1 CL E G H2317513345ORPHA:99845Genetic recurrent myoglobinuria95
HP:0011037HP:0100519Anuria1MYH11 CL E G H46297569OMIM:619351MEGACYSTIS-MICROCOLON-INTESTINAL HYPOPERISTALSIS SYNDROME 2; MMIHS2418
HP:0011037HP:0100520Oliguria1PAX2 CL E G H50768616ORPHA:97362Renal hypoplasia, bilateral39
HP:0011037HP:0100520Oliguria1PBX1 CL E G H50878632ORPHA:97362Renal hypoplasia, bilateral3
HP:0011037HP:0100520Oliguria1PKHD1 CL E G H53149016ORPHA:731Autosomal recessive polycystic kidney diseaseHP:0040283 - Occasional563
HP:0011037HP:0100519Anuria1REN CL E G H59729958OMIM:267430Renal tubular dysgenesis.25
HP:0011037HP:0100520Oliguria1RYR1 CL E G H626110483ORPHA:466650Exercise-induced malignant hyperthermiaHP:0040283 - Occasional1200
HP:0011037HP:0100520Oliguria1SLC22A12 CL E G H11608517989OMIM:220150Hypouricemia, renal, 156
HP:0011037HP:0100520Oliguria1SLC25A20 CL E G H7881421ORPHA:159Carnitine-acylcarnitine translocase deficiencyHP:0040283 - Occasional40
HP:0011037HP:0100519Anuria1THBD CL E G H705611784OMIM:612926Hemolytic uremic syndrome, atypical, susceptibility to, 6.60


Genes (29) :ACE AGT AGTR1 APRT C3 CAV1 CCN2 CCR6 CD46 CFB CFH CFHR1 CFHR3 CFI COX1 COX3 DZIP1L HLA-DRB1 IRF5 LPIN1 MYH11 PAX2 PBX1 PKHD1 REN RYR1 SLC22A12 SLC25A20 THBD

Diseases (17) :OMIM:267430 ORPHA:976 OMIM:614723 OMIM:612925 ORPHA:220393 OMIM:612922 OMIM:612924 OMIM:235400 OMIM:612923 ORPHA:99845 ORPHA:731 OMIM:619351 ORPHA:97362 ORPHA:466650 OMIM:220150 ORPHA:159 OMIM:612926
 

Human Phenotype Ontology(HPO) is developed by the Human Phenotype Ontology Consortium. The version used here is December 15 2022 release.